Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

Symphogen A/S. (1/12/16). "Press Release: Symphogen to Present at JPMorgan Conference in San Francisco, CA". Copenhagen.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Symphogen A/S
  Group Symphogen (Group)
  Organisation 2 Baxalta Inc. (NYSE: BXLT)
  Group Shire (Group)
Products Product J.P. Morgan 34th Annual Healthcare Conference 2016 San Francisco
  Product 2 Sym004 (anti-cancer pAb)
Persons Person Drejer, Kirsten (Symphogen 2000–201608 Founding CEO since 201609 Executive Director)
  Person 2 Olin, Martin (Symphogen 201609– CEO before CFO since 201204 before SLS Invest + Novo Nordisk)

Symphogen, a private biopharmaceutical Company developing recombinant antibody mixtures, announced today that Kirsten Drejer, Chief Executive Officer, will present an update on the Company at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 from 11:00 AM - 11.25 AM at San Francisco's Westin St. Francis Hotel in the Elizabethan D meeting room. The company announced earlier this month a strategic collaboration with Baxalta Incorporated, worth up to $1.6 billion plus royalties, to develop immuno-oncology candidate products.

Pipeline Overview

Symphogen's most advanced drug candidate, Sym004, is currently being investigated in clinical studies in multiple cancer indications. Most progressed is a fully enrolled Phase 2b study in 254 patients with metastatic colorectal cancer (mCRC) and with acquired resistance to anti-EGFR antibody therapies, which is being conducted in the USA and Europe. Positive efficacy clinical findings from a previous study of Sym004 in the same patient population were published for the first time in the peer-reviewed journal, Cancer Discovery, in June 2015. Two additional drug candidates Sym015 (anti-MET) and Sym013 (anti-pan-HER) are expected to enter the clinic during 2016. Symphogen has built an innovative portfolio of early-stage immuno-oncology programs based on the company's expertise in this field and its productive technology suite - capable of identifying, selecting, and manufacturing therapeutic antibodies and antibody mixtures. In early 2016 this resulted in a broad strategic collaboration with the US-based global biopharmaceutical Company, Baxalta, to advance novel therapeutics against six immuno-oncology targets. This collaboration was designed to build upon the rapidly expanding field of immunological checkpoint blockade which offers patients with improved efficacy in fighting a variety of cancers."

About Symphogen A/S

Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use. The European-based company is developing next-generation antibody therapeutics for the treatment of cancer. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product. The company has collaborations for the development of antibody therapeutics in the infectious disease area with Genentech and in immuno-oncology with Baxalta Incorporated. Symphogen employs more than 90 people, has offices in Denmark and New Jersey, US and its investors include Essex Woodlands Health Ventures, Novo A/S, PKA, Sunstone Capital, Gilde Healthcare Partners, Danica Pension, Takeda Ventures, Inc., and Genentech. For more information, please see

For additional information, please contact:

Kirsten Drejer
Chief Executive Officer
Phone: + 45 22 10 99 59

Martin Olin
Chief Financial Officer
Phone: + 45 40 21 85 32

Consilium Strategic Communications
Mary-Jane Elliott, Amber Fennell, Lindsey Neville
Phone: +44 20 3709 5700

Annes Associates
Shari Annes
Phone: 650-888-0902

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Symphogen (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top